← back to search

Daniela Sia

Dana-Farber Cancer Institute · US
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Hepatocellular Carcinoma Treatment and Prognosis, Hepatitis B Virus Studies, and Cholangiocarcinoma and Gallbladder Cancer Studies.
h-index
42
citations
13,677
works
193
NIH funding
primary concept
Medicine
email

Recent publications

Role of the stromal and immune microenvironment in intrahepatic cholangiocarcinoma
JHEP Reports 2026cited by 0position: contributordoi
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.
2025cited by 2position: contributordoi
Spatial immune scoring and prediction of HCC outcomes.
2025cited by 0position: contributordoi
Data from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
2025cited by 0position: contributordoi
Supplementary Data 1 from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
2025cited by 0position: contributordoi
Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2025cited by 0position: contributordoi
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
2024cited by 16position: contributordoi
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
2023cited by 191position: contributordoi
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
2023cited by 120position: contributordoi
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy
Gut 2023cited by 23position: middledoi
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
2023cited by 13position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Data from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Data from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Data from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Data from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Data from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi
Supplementary Figure from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Josep M. Llovet · Mayo Clinic in Florida62 papers (2013–2025) · 43 papers (2020–2025) · 42 papers (2021–2026) · 39 papers (2019–2023)Laura Torrens · Tisch Hospital38 papers (2020–2023) · 37 papers (2021–2023) · 36 papers (2021–2023)Andrew Uzilov · Sema4 (United States)36 papers (2021–2023)Patricia Taik · Sema4 (United States)36 papers (2021–2023)Xavier Forns · Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer35 papers (2022–2023)Jessica Zucman‐Rossi · Inserm35 papers (2022–2023)Éric Letouzé · Centre National de la Recherche Scientifique35 papers (2022–2023) · 35 papers (2022–2023)Genís Campreciós · Centro de Investigación Biomédica en Red35 papers (2022–2023) · 35 papers (2022–2023) · 35 papers (2022–2023)Roger Esteban-Fabró · Breast Cancer Research Foundation35 papers (2022–2023) · 35 papers (2022–2023)Mireia García-López · Hospital Vega Baja35 papers (2022–2023)Sofía Pérez-del-Pulgar · Centro de Investigación Biomédica en Red35 papers (2022–2023)